



Philanthropic Funds



A portfolio approach to your philanthropic support

MCRI is inviting like-minded, impact-driven philanthropists to join forces and co-invest into one of three collective philanthropic funds.

Co-investing into one of MCRI's Philanthropic Funds will help us make an even greater difference to paediatric research, and the health of children both in Australia and globally.



Brilliant Minds Fund

Supporting the career of a talented researcher is undoubtedly one of the most valuable investments that can be made for the Institute, individual researchers, and the field of child health research. Our exceptional researchers are a key reason why we are ranked in the top 3 child health research institutes globally.



Discovery Fund

Providing funding for MCRI's promising projects and pilot studies is an exciting and proven way to accelerate groundbreaking discoveries in medical research. Our expertise and state-of-the-art technology, combined with your support, can kick-start the next revolutionary project.




Innovation Fund

By seed funding projects with the greatest potential to deliver real world outcomes, our innovative research can be converted into life-changing improvements in the communities which children live, learn and grow. As the largest child health research Institute in Australia, we have unlimited potential to deliver broad social impact across the globe.

“By working with others, I know that my contribution is valuable and can have even greater impact.”

Philanthropic Funds Donor



Brilliant Minds Fund

Our Brilliant Minds Fund supports the best and brightest MCRI researchers at critical stages in their careers, enabling the Institute to retain the best talent whose research holds great promise.

Your investment will ensure that we address the “leaky pipeline” occurring in medical research whereby young, talented researchers are leaving the field as they cannot compete with more established researchers when seeking highly-competitive government funding. Your funds will help secure their future in research.

Our world-leading researchers are driven to transform child health for all. Here is just one example.

Investing in people for impact

MCRI's Professor Angela Morgan is passionate about understanding the cause of persistent and severe speech and language disorders, including in children who have suffered from a stroke. Prof Morgan was generously supported by a fellowship for four years, which allowed her to pursue early-stage ideas and build her own research program. Because of that early support, Angela now leads the prestigious NHMRC Centre for Research Excellence into Speech & Language - an international collaboration of experts in the fields of speech pathology, paediatric neurology, neuroscience, genetics and bioinformatics.

This work is pioneering our understanding of the neurobiology of speech and language disorders and the identification of new gene pathways that lead to child speech and language disorders.



"I am extremely grateful to the collective of donors through MCRI who have supported my work and enabled me to explore novel ideas and expand the horizons of my research."

Professor Angela Morgan

Discovery Fund

Our Discovery Fund will accelerate ground-breaking discoveries in medical research by providing seed funding for one-of-a-kind, proof-of-concept projects that show huge potential. Combined with our expertise and in-house state-of-the-art technology, together we can enable the next revolutionary research discovery or innovation.


Our experts are dedicated to taking basic research to new heights. Here is just one example.

Sarah Cohen (pictured right) was born with Achondroplasia, the most common form of dwarfism.

Achondroplasia is a genetic bone disorder caused by a default in a gene that turns on a switch and decreases bone growth. Aside from short stature, children with Achondroplasia suffer from a raft of medical problems throughout their life and need recurrent surgeries. The disorder also puts the child at a 45 times higher risk of sudden infant death in the first five years of their life.

Thanks to investment in drug discovery and precision therapy there is now a drug that can target the cause of Achondroplasia and boost bone growth. Now in a Phase III clinical placebo-controlled trial, the drug Vosoritide is proving to be both safe and effective at treating children aged 5-18 years with Achondroplasia and is on the pathway to worldwide approval for clinical use.





Prof Ravi Savarirayan is leading the global investigation of Vosoritide and collaborating with experts from the U.S.A., U.K., Germany, Japan, Spain, and Turkey. Prof Savarirayan has been working for MCRI for 20 years and has been supported by MCRI philanthropic funds and successful with highly-competitive grants.

“During the trial we’ve seen Sarah grow up at the same rate as her friends. She can now join in bike rides with her friends, and loves being allowed on our local waterslide.”

Paul Cohen, Sarah’s father

Innovation Fund

Our Innovation Fund will kick-start research projects at the cusp of translation, allowing our experts to complete essential pre-clinical trial testing of novel therapeutics or interventions, and facilitate community implementation and policy reform. Ultimately, your support will enable a specific social impact outcome to be targeted.

At MCRI we are committed to ensuring that all children have the opportunity to live a healthy and fulfilled life. Here is just one example.


1 in 5 children will suffer a concussion by the age of 16.

However, most concussion injuries do not result in loss of consciousness, so it is important for parents and care-givers to identify and treat accordingly. Like all injuries to the body- the brain also needs proper time to rest and recover. If left untreated, or without proper care, the child is at risk of long-term consequences.

Developed by world-leading concussion experts at the MCRI and Melbourne's The Royal Children's Hospital (RCH) and in partnership with the AFL, the HeadCheck app helps parents, trainers, and teachers, to recognize the signs of concussion and decide on a suitable course of action.

Research into concussion was originally supported untied philanthropic support. The idea to translate this research into the Headcheck app was supported by commercial funding including the AFL.

The app now has more than 55,000 downloads.



www.headcheck.com.au

Together we can shape the future

With this collective giving strategy, we can leverage up-and-coming researchers and their projects, to ultimately improve the prediction, prevention, diagnosis and treatment of disease in children.

The opportunity to impact child health is enormous.


MCRI welcomes passionate philanthropists to consider to co-invest into one of our collective funds.

All supporters will receive exclusive updates and an annual impact report on the fund they have selected to invest in.

If you have any questions or wish to discuss this opportunity further, please don't hesitate to contact:

Matthew Hannan
Head of Engagement and Philanthropy
M: 0412 175 111
E: Matthew.Hannan@mcri.edu.au





“Murdoch Children’s Research Institute is a world-leading paediatric research institute. Our 1200 strong research team is committed to tackling the biggest problems in child health globally. No matter where a child is born, MCRI can change the course of their life for the positive. Through funding their work, together we can fundamentally change the lives of children everywhere.”

**Sarah Murdoch
Co-Chair and Global Ambassador,
Murdoch Children’s Research Institute**



5th Floor, Royal Children's Hospital
Parkville VIC 3052 Australia

+61 3 8341 6200

philanthropy@mcri.edu.au

mcri.edu.au/get-involved

